InflaRx NV (InflaRx NV) Cash-to-Debt : 75.95 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. InflaRx NV's cash to debt ratio for the quarter that ended in Mar. 2024 was 75.95.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, InflaRx NV could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for InflaRx NV's Cash-to-Debt or its related term are showing as below:

IFRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 54.18 Med: 141.48 Max: No Debt
Current: 75.95

During the past 9 years, InflaRx NV's highest Cash to Debt Ratio was No Debt. The lowest was 54.18. And the median was 141.48.

IFRX's Cash-to-Debt is ranked better than
76.54% of 1539 companies
in the Biotechnology industry
Industry Median: 6.49 vs IFRX: 75.95

InflaRx NV Cash-to-Debt Historical Data

The historical data trend for InflaRx NV's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

InflaRx NV Cash-to-Debt Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

136.51

144.93

58.22

60.31

80.56

InflaRx NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															54.18	87.35	101.86	80.56	75.95

Competitive Comparison of InflaRx NV's Cash-to-Debt

For the Biotechnology subindustry, InflaRx NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Cash-to-Debt falls into.

InflaRx NV Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

InflaRx NV's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	98.443	/	(0.408	+	0.814)
	=	80.56

InflaRx NV's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	91.213	/	(0.411	+	0.79)
	=	75.95

InflaRx NV (NAS:IFRX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

InflaRx NV Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.